Price
$3.35
Increased by +1.82%
Dollar volume (20D)
3.35 M
ADR%
6.49
Earnings report date
May 23, 2025
Shares float
485.07 M
Shares short
6.63 M [1.37%]
Shares outstanding
153.85 M
Market cap
630.80 M
Beta
0.97
Price/earnings
N/A
20D range
3.11 3.94
50D range
3.11 4.72
200D range
2.52 5.02

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.

It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.

The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials.

In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency.

The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab.

Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Nov 12, 24 -0.10
Decreased by -392.00%
-
Sep 5, 24 -0.09
Decreased by N/A%
-0.01
Decreased by -762.00%
May 15, 24 -0.06
Decreased by -219.50%
-
Nov 17, 23 0.00
Decreased by N/A%
-
Sep 7, 23 -0.02
Increased by +85.64%
-0.02
May 31, 23 0.00
Decreased by -100.00%
-
Mar 28, 23 -0.02
Increased by +91.61%
-
Aug 11, 21 0.00
Increased by +100.00%
-0.14
Increased by +100.00%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 24 0.00
Decreased by -100.00%
-15.00 M
Decreased by -128.68%
Decreased by N/A%
Decreased by N/A%
Jun 30, 24 0.00
Decreased by -100.00%
-12.26 M
Increased by +9.90%
Decreased by N/A%
Decreased by N/A%
Mar 31, 24 0.00
Decreased by N/A%
-8.95 M
Increased by +25.88%
Decreased by N/A%
Decreased by N/A%
Dec 31, 23 361.10 K
Decreased by -89.87%
-6.05 M
Increased by +65.76%
Decreased by -1.67 K%
Decreased by -237.95%
Sep 30, 23 533.43 K
Decreased by -20.97%
-6.56 M
Increased by +73.58%
Decreased by -1.23 K%
Increased by +66.57%
Jun 30, 23 8.79 M
Increased by +N/A%
-13.60 M
Decreased by N/A%
Decreased by -154.74%
-
Mar 31, 23 0.00
Decreased by N/A%
-12.08 M
Decreased by N/A%
Decreased by N/A%
-
Dec 31, 22 3.56 M
Increased by +N/A%
-17.66 M
Decreased by N/A%
Decreased by -495.48%
-
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY